McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT

McNicoll, Lewis & Vlak reiterated its Vivus VVUS Buy rating and $16 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Although FORTRESS will have a greater number of dyads (mother-infant pairs), it will be similar in methodology and design to the Wolters Kluwer study (Exhibit 1). Therefore, we will compare the relative risks and confidence intervals of FORTRESS to that of the Wolters Kluwer data. If these are similar, we believe the FDA and EMEA will conclude that topiramate is not a major teratogen." Shares of Vivus were trading at $7.36 at the time of posting, down 1.47% from Tuesday's market close.